Animal & Plant Derived Vaccines

It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.


    Related Conference of Animal & Plant Derived Vaccines

    February 15-16, 2023

    11th World Summit on Immunology and Immunotherapy

    Zurich, Switzerland
    February 20-21, 2023

    Global Summit on SARS-CoV-2 virus

    Madrid, Spain
    May 24-25, 2023

    37th International Conference on Immunology

    Vienna, Austria

    Animal & Plant Derived Vaccines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in